期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 100, 期 -, 页码 137-140出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2016.02.006
关键词
Sorafenib; Autophagy; Targeting kinase inhibitor; Acquired resistance
资金
- Zhejiang Province Natural Science Foundation of China [LY15H180003]
Targeting kinase inhibitors (TKIs) are effective tools for treating advanced cancer. However, acquired resistance represents a roadblock in the use of TKIs, such as sorafenib, for cancer therapy. Understanding the acquisition of resistance to sorafenib will help doctors to cope with acquired resistance to TKIs in general and to develop personalized medicine strategies for cancer patients. Autophagy is a biological process that occurs in normal organisms. However, it is also a component of multiple disease processes, including cancer development and progression. However, the roles of autophagy in cancer and in response to cancer therapy are controversial. Id this review, we summarize the progress in autophagy and sorafenib resistance research, which is representative of acquired resistance to targeted cancer therapy. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据